Cargando…
Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351841/ https://www.ncbi.nlm.nih.gov/pubmed/32451571 http://dx.doi.org/10.1007/s00125-020-05175-8 |
| _version_ | 1783557526161195008 |
|---|---|
| author | Ziegler, Anette-Gabriele Bonifacio, Ezio |
| author_facet | Ziegler, Anette-Gabriele Bonifacio, Ezio |
| author_sort | Ziegler, Anette-Gabriele |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7351841 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73518412020-07-14 Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? Ziegler, Anette-Gabriele Bonifacio, Ezio Diabetologia Letter Springer Berlin Heidelberg 2020-05-26 2020 /pmc/articles/PMC7351841/ /pubmed/32451571 http://dx.doi.org/10.1007/s00125-020-05175-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter Ziegler, Anette-Gabriele Bonifacio, Ezio Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
| title | Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
| title_full | Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
| title_fullStr | Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
| title_full_unstemmed | Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
| title_short | Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
| title_sort | why is the presence of autoantibodies against gad associated with a relatively slow progression to clinical diabetes? |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351841/ https://www.ncbi.nlm.nih.gov/pubmed/32451571 http://dx.doi.org/10.1007/s00125-020-05175-8 |
| work_keys_str_mv | AT ziegleranettegabriele whyisthepresenceofautoantibodiesagainstgadassociatedwitharelativelyslowprogressiontoclinicaldiabetes AT bonifacioezio whyisthepresenceofautoantibodiesagainstgadassociatedwitharelativelyslowprogressiontoclinicaldiabetes |